Market Report: TAKING STOCK
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.rIs the American love-in with JD Wetherspoon, the highly-rated pubs chain, coming to an end? A US investment group has been an avid Wetherspoon follower, helping to drive the shares to a peak of 1,053p. But in recent weeks there has been talk of US disenchantment and although there is no evidence of US selling the shares have fallen; they lost a further 51p to 895p.
rMedeva, bumping along at 238p, should lift profits to pounds 103.5m this year from pounds 79m, say Societe Generale Strauss Turnbull.
Analysts Paul Diggle and Alyson Coates are impressed by the acquisition of the US Rochester group. They are looking for profits to move further ahead to pounds 134m next year and regard the shares a buy.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments